Key facts
- Robert F. Kennedy Jr. is visiting key battleground districts as part of his "Take Back Your Health" tour.
- These districts are considered crucial for determining congressional majorities.
- Kennedy's supporters have endorsed Republican candidates in some of these districts.
- The White House views Kennedy's alliance with Donald Trump as a strategic advantage for the GOP.
Robert F. Kennedy Jr. is actively visiting key battleground districts across the United States as part of his "Take Back Your Health" tour. While these visits are not framed as official campaign events, they are occurring in districts considered critical for determining congressional majorities in the upcoming elections. The White House views Kennedy's alliance with Donald Trump as a strategic advantage for the GOP, hoping his presence will help the party maintain its congressional majorities.
Kennedy's tour, which began in January in Harrisburg, Pennsylvania, has focused on promoting his agenda to improve the quality of American food and address chronic diseases. His policy proposals, such as improving food quality, have shown popularity among Americans, sometimes more so than his stances on vaccine recommendations for children. His tour has included stops in districts represented by Republican lawmakers, including Rep. Scott Perry in Pennsylvania, Rep. Monica De La Cruz in Texas, and areas near Richmond, Virginia.
Some of the districts Kennedy has visited are highly competitive. For instance, Rep. Barrett, who has received endorsements from groups affiliated with Kennedy's "Make America Healthy Again" movement, won his 2024 race by a narrow margin. Similarly, Rep. Van Orden secured his second term by less than three points, and freshman Rep. Evans won by less than one point. Even Rep. Kaptur, seeking her 23rd term, narrowly won her working-class district in 2024.
Kennedy has also made appearances in districts with a Democratic edge, such as Concord, New Hampshire, and Duarte, California, to discuss health-related initiatives like fighting Lyme disease and cancer research.